Showing all 4 results

  • Placeholder

    Crizalk (Crizotinib) – 250 Mg

    0 out of 5
    Price range: $868 through $1,727

    Crizalk 250 mg is an oral capsule formulation of crizotinib, a precision tyrosine kinase inhibitor developed for treatment of advanced or metastatic non‑small cell lung cancer (NSCLC) with specific genetic alterations. It inhibits ALK, ROS1, and MET‑exon 14 skipping mutations to halt cancer cell proliferation and improve survival outcomes in responsive patients.

    Select optionsDone This product has multiple variants. The options may be chosen on the product page
  • Placeholder

    Xovoltib 30 Mg (Afatinib Dimaleate)

    0 out of 5
    Price range: $868 through $2,436

    Xovoltib 30 mg is an oral tablet delivering afatinib dimaleate, a second-generation irreversible inhibitor of EGFR and HER2 tyrosine kinases. Designed for patients with advanced or metastatic non‑small cell lung cancer (NSCLC) that harbor activating EGFR mutations, including L858R and exon 19 deletion, or certain HER2-positive tumors. It improves tumor control by blocking key signaling pathways driving cancer growth.

    Select optionsDone This product has multiple variants. The options may be chosen on the product page
  • Placeholder

    Xovoltib 40 Mg (Afatinib Dimaleate)

    0 out of 5
    Price range: $966 through $2,772

    Xovoltib 40 mg is an oral afatinib dimaleate tablet offering a powerful, irreversible inhibition of EGFR and HER2 tyrosine kinases. It is used for advanced or metastatic non‑small cell lung cancer (NSCLC) driven by activating EGFR mutations, and may benefit select HER2-positive cases. As the highest commonly available dose, it supports potent systemic therapy where lower doses are insufficient or disease-resistant

    Select optionsDone This product has multiple variants. The options may be chosen on the product page
  • Placeholder

    Xovoltib 50 Mg (Afatinib Dimaleate)

    0 out of 5
    Price range: $998 through $2,826

    Xovoltib 50 mg contains afatinib dimaleate, a second-generation, irreversible tyrosine kinase inhibitor targeting EGFR and HER2 receptors. Designed for patients with advanced or metastatic non‑small cell lung cancer (NSCLC) driven by activating EGFR mutations, this 50 mg dose offers intensified exposure for individuals who require potent systemic therapy beyond lower dose options.

    Select optionsDone This product has multiple variants. The options may be chosen on the product page

End of content

End of content